Company intelligence / Profile preview

Landcent

Shanghai, China

Ownership: Private
Development stage: Other

Overview

Landcent develops innovative vector control products including insecticide-treated bednets (Neonet, Neonet NG) and anti-malarials (Codispaq) for malaria prevention, with emerging solutions like Bacitin for larval control. Products have undergone field trials, semi-field trials, and received ECHA approval for Europe.[3][4]

Therapeutic areas: Infectious Diseases
Modalities: BiopesticideLong-Lasting Insecticidal NetsAnti-Malarial
Industry: Biotech

Drug pipeline

1 asset

Codispaq

Preclinical

Partnerships

Bill & Melinda Gates FoundationShanghai Institute of Organic Chemistry (SIOC)China CDCWHO GCDPPRLS IndiaPharmaSymbiosis

Beyond the preview

Go deeper on Landcent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Landcent.

Explore the full profile